nanoZER-Novel treatment for cancer | 8437
Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

nanoZER-Novel treatment for cancer

14th Annual Conference on Translational Medicine and Oncologists Meet

November 28-30, 2016 San Francisco, USA

Heshu S Rahman, Hemn H Othman1and Rasedee A

Universiti Putra Malaysia, Malaysia

Scientific Tracks Abstracts: Transl Med

Abstract :

Cancer nanotherapy is progressing rapidly with the introduction of many innovative drug delivery systems to replace conventional therapy. Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25�?°C) was used in this investigation. The zerumbone was loaded into nanostruc�?¬tured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68�?±0.1 nm and a polydispersity index of 0.29�?±0.004 �?¼m. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was â�?�?25.03�?±1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64�?±0.38 �?¼g/mL, and for free zerumbone was 5.39�?±0.43 �?¼g/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia. Although the antitumor activity of zerumbone (ZER) has been reported, there has been no information available on the effect of ZER-loaded nanostructured lipid carrier (NLC) (nanoZER) on murine leukemia cell. The in vitro and in vivo effects of nanoZER on murine leukemia induced with WEHI-3B cells were investigated. The results from 3-[4,5-dimethylthiazol-2-yl]-2,5-iphenyltetrazolium bromide, Hoechst 33342, Annexin V, cell cycle, and caspase activity assays showed that the growth of leukemia cells in vitro was inhibited by nanoZER. In addition, outcomes of histopa�?¬thology, transmission electron microscopy, and Tdt-mediated dUTP nick-end labeling analyses revealed that the number of leukemia cells in the spleen of BALB/c leukemia mice significantly decreased after 4 weeks of oral treatment with various doses of nanoZER. Western blotting and reverse-transcription quantitative polymerase chain reaction assays confirmed the anti-leukemia effects of nanoZER. In conclusion, nanoZER was shown to induce a mitochondrial-dependent apoptotic pathway in murine leukemia. Loading of ZER in NLC did not compromise the anti-cancer effect of the compound, suggesting nanoZER as a promising and effective delivery system for treatment of cancer.

Biography :

Heshu S Rahman obtained her PhD from Universiti Putra Malaysia in 2014 in the field of Hematology and Clinical Pathology. Her thesis was granted as best PhD thesis at the Universiti Putra Malaysia for year 2014. Her research areas include the development of alternative treatments for cancers and nanoparticles development for drug delivery. The nanoZER (WO2014/123406 A1) is one of the products of her research. She is currently a Senior Lecturer at the Faculty of Veterinary Medicine, Univerisiti Putra Malaysia. She has published more than 100 journal and proceeding articles, produced 6 patents and received 10 awards including Gold, Silver and Bronze Medals.